Marker Therapeutics (NASDAQ:MRKR) Announces Earnings Results

Marker Therapeutics (NASDAQ:MRKR) announced its quarterly earnings data on Wednesday. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.17, FiscalAI reports. The company had revenue of $1.10 million during the quarter, compared to analyst estimates of $0.68 million. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%.

Marker Therapeutics Trading Down 1.5%

Shares of MRKR traded down $0.02 during trading hours on Wednesday, reaching $1.34. 73,138 shares of the company’s stock traded hands, compared to its average volume of 328,446. Marker Therapeutics has a 12 month low of $0.81 and a 12 month high of $4.07. The stock has a market cap of $22.34 million, a PE ratio of -1.09 and a beta of 1.42. The firm’s 50 day simple moving average is $1.63 and its 200-day simple moving average is $1.29.

Institutional Investors Weigh In On Marker Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC purchased a new position in Marker Therapeutics in the 4th quarter worth approximately $222,000. Geode Capital Management LLC raised its position in shares of Marker Therapeutics by 35.3% during the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after buying an additional 34,028 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Marker Therapeutics by 16.4% during the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock valued at $184,000 after buying an additional 17,400 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Marker Therapeutics by 16.5% during the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after acquiring an additional 13,340 shares during the last quarter. Finally, LPL Financial LLC grew its position in Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after acquiring an additional 24,500 shares in the last quarter. 22.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MRKR has been the topic of several recent research reports. HC Wainwright started coverage on Marker Therapeutics in a research report on Monday, December 8th. They set a “buy” rating and a $10.00 target price on the stock. Zacks Research lowered Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Wall Street Zen raised Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.